Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma

Lu,Zhong‑Wu; Wen,Duo; Wei,Wen‑Jun; Han,Li‑Tao; Xiang,Jun; Wang,Yu‑Long; Wang,Yu; Liao,Tian; Ji,Qing‑Hai

doi:10.3892/or.2020.7458

Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma

Authors:
- Zhong‑Wu Lu
- Duo Wen
- Wen‑Jun Wei
- Li‑Tao Han
- Jun Xiang
- Yu‑Long Wang
- Yu Wang
- Tian Liao
- Qing‑Hai Ji
View Affiliations

Affiliations: Department of Head and Neck Surgery, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
Published online on: January 9, 2020 https://doi.org/10.3892/or.2020.7458
Pages: 783-794
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endeavors towards identifying key molecular markers for early diagnosis and treatment are driving the clinical study of papillary thyroid carcinoma (PTC). Recent studies have indicated that protein phosphatase, Mg2+/Mn2+ dependent, 1D (PPM1D) exerts an oncogenic function by increasing cell proliferation, migration and invasion in various cancer types. In addition, PPM1D has a high frequency of genetic alterations and has been proposed as a tumor driver in thyroid cancer, making PPM1D an attractive potential oncotarget for cancer treatment. The aims of the present study were to investigate the downstream targets of PPM1D and the potential molecular mechanisms of its oncogenic activities, as well as its clinical significance in PTC. As anticipated, PPM1D overexpression was confirmed in PTC clinical specimens. Furthermore, knockdown of PPM1D in thyroid cancer cell lines significantly suppressed the proliferation, migration and invasion but facilitated cell apoptosis. The protein levels of phosphorylated p38 mitogen‑activated protein kinase (MAPK), p53 and Bax were increased in PPM1D‑knockdown cells, while inhibition of p38 phosphorylation restored cell migration, proliferation and cell apoptosis. In addition, silencing of PPM1D expression induced nuclear translocation of p53 in K‑1 and TPC‑1 cells. The present results demonstrated that PPM1D regulated p38 MAPK and p53 signaling pathways to promote thyroid cancer progression. Collectively with the clinical results, these data qualified PPM1D as a potential diagnostic biomarker and therapeutic target in human thyroid cancer.

View Figures

View References

1	Cabanillas ME, McFadden DG and Durante C: Thyroid cancer. Lancet. 388:2783–2795. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lubitz CC and Sosa JA: The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer. 122:3754–3759. 2016. View Article : Google Scholar : PubMed/NCBI
3	Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho C, Krishnamoorthy GP, Xu B, et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 126:1052–1066. 2016. View Article : Google Scholar : PubMed/NCBI
4	Le Guezennec X and Bulavin DV: WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem Sci. 35:109–114. 2010. View Article : Google Scholar : PubMed/NCBI
5	Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ, Gabriele T, McCurrachM E, Marks JR, Hoey T, et al: Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 31:133–134. 2002. View Article : Google Scholar : PubMed/NCBI
6	Tamura S, Toriumi S, Saito JI, Awano K, Kudo TA and Kobayashi T: PP2C family members play key roles in regulation of cell survival and apoptosis. Cancer Sci. 97:563–567. 2006. View Article : Google Scholar : PubMed/NCBI
7	Pullen KE, Ng HL, Sung PY, Good MC, Smith SM and Alber T: An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase. Structure. 12:1947–1954. 2004. View Article : Google Scholar : PubMed/NCBI
8	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
9	Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wang ZP, Tian Y and Lin J: Role of wild-type p53-induced phosphatase 1 in cancer. Oncol Lett. 14:3893–3898. 2017. View Article : Google Scholar : PubMed/NCBI
11	Harrison M, Li J, Degenhardt Y, Hoey T and Powers S: Wip1-deficient mice are resistant to common cancer genes. Trends Mol Med. 10:359–361. 2004. View Article : Google Scholar : PubMed/NCBI
12	Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 31:210–215. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cancer Genome Atlas Research N, . Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
14	Chew J, Biswas S, Shreeram S, Humaidi M, Wong HET, Dhillion MK, Teo H, Hazra A, Fang CC, López-Collazo D, et al: WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol. 11:659–666. 2009. View Article : Google Scholar : PubMed/NCBI
15	Tan DS, Maryou B, Lambros K, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 15:2269–2280. 2009. View Article : Google Scholar : PubMed/NCBI
16	Goloudina AR, Kochetkova EY, Pospelova TV and Demidov ON: Wip1 phosphatase: Between p53 and MAPK kinases pathways. Oncotarget. 7:31563–31571. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
18	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
19	Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM and Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI
20	Lu X, Nannenga B and Donehower LA: PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19:1162–1174. 2005. View Article : Google Scholar : PubMed/NCBI
21	Demidov ON, Timofeev O, Lwin HNY, Kek C, Appella E and Bulavin DV: Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell. 1:180–190. 2007. View Article : Google Scholar : PubMed/NCBI
22	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
23	Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC, Appella E and Bulavin DV: Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle. 12:2656–2664. 2013. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Li N, Xiang R and Sun P: Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 39:268–276. 2014. View Article : Google Scholar : PubMed/NCBI
25	Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y and Imai K: p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19:6517–6526. 2000. View Article : Google Scholar : PubMed/NCBI
26	Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E and Fornace AJ Jr: Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet. 36:343–350. 2004. View Article : Google Scholar : PubMed/NCBI
27	Wen D, Liao T, Ma B, Qu N, Shi RL, Lu ZW, Wang YL, Wei WJ and Ji QH: Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/beta-catenin signaling and sensitizes cancer cells to FH535 therapy. Cancer Med. 7:285–296. 2018. View Article : Google Scholar : PubMed/NCBI
28	Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenga S, Miccoli P and Antonelli A: New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 16:6153–6182. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tang YL, Liu X, Gao SY, Feng H, Jiang YP, Wang SS, Yang J, Jiang J, Ma XR, Tang YJ, et al: WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C. Oncotarget. 6:9031–9044. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sun GG, Wang YD, Liu Q and Hu WN: Expression of Wip1 in kidney carcinoma and its correlation with tumor metastasis and clinical significance. Pathol Oncol Res. 21:219–224. 2015. View Article : Google Scholar : PubMed/NCBI